Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Pharma
JPM25: Regeneron has few answers for declining sales of Eylea HD
Regeneron had little explanation for a decline in sales of Eylea HD from $392 million in 2024's third quarter to $305 million in the fourth quarter.
Kevin Dunleavy
Jan 14, 2025 10:25am
Verona's new COPD drug Ohtuvayre racked up sales of $42M in 2024
Jan 7, 2025 1:27pm
Eylea HD passes test in retinal vein occlusion, teeing up filing
Dec 18, 2024 8:20am
Checkpoint passes FDA checkpoint for PD-L1 drug Unloxcyt
Dec 16, 2024 10:59am
Asian patients with PCV show improvement with Roche's Vabysmo
Nov 22, 2024 7:00am
Eylea HD sales jump in Q3 but Regeneron still cedes market share
Oct 31, 2024 11:37am
